Alluvi, previously BI 4744, offers a significant advance in obesity treatment. This dual agonist targeting both GLP-1 and GIP sites demonstrates compelling efficacy in research assessments, arguably exceeding current https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/